Presenter: John Seibyl, M.D. | Distinguished Scientist, Invicro

Tau PET  imaging is now commonly incorporated as an imaging biomarker in clinical research trials in Alzheimer’s and other tauopathies, particularly regarding serial longitudinal change in the evaluation of therapeutics designed to slow the course of disease. Both qualitative and quantitative assessments provide useful corroborative reporting endpoints.

The methods which operationalize these outcome measures, based on an understanding of the dynamic pathophysiology of brain tau deposition and its phenomenological manifestations on the PET scan are described for different tau radiopharmaceuticals, along with implications for future clinical and clinical research applications.

In this webinar, the presenter will:

• Describe the differences between Amyloid and Tau PET with regard to pathophysiology and differing roles in clinical research trials
• Describe the methodology and its validation for performing the visual interpretation of different Tau PET imaging agents
• Explain the advantages and disadvantages of quantitative versus qualitative Tau PET assessments for questions posed in clinical research